Eli Lilly's Oral GLP-1 Drug Foundayo Captures One-Third of New Patients; $6.5 Billion Houston Facility Breaks Ground
nashnova research
Lilly CEO Ricks says roughly one-third of all new oral GLP-1 patients are now on Foundayo, as the company breaks ground on a $6.5 billion Houston factory — the capacity arms race has entered the oral-drug era.
How much market has Foundayo grabbed in two months?
Ricks told CNBC on Monday that about one-third of all new oral GLP-1 patients are taking Foundayo.
The drug entered the U.S. market only in April. Uptake has been solid, but Lilly still trails Novo Nordisk in the oral GLP-1 space.
This means → Foundayo proves Lilly can win share in oral form, but the "challenger" label has not come off yet.
How much did its first full quarter bring in?
Lilly disclosed in August that Foundayo posted $98 million in sales in Q2 — its first full quarter on the market.
Medicare coverage for obesity drugs took effect in July, opening a wider reimbursement channel.
This means → with Medicare now live, prescription volumes for both Foundayo and Lilly's blockbuster weight-loss drug Zepbound could accelerate further.
What will the $6.5 billion Houston plant do?
Ricks made the comments at a groundbreaking ceremony for a new plant on roughly 240 acres at Houston's Generation Park.
The $6.5 billion facility is scheduled to be operational by 2030. It will primarily produce Foundayo's active ingredient and also manufacture small-molecule APIs across cardiometabolic, oncology, immunology, and neuroscience programs.
In plain terms = Lilly is not building a factory for one drug — it is bundling oral-drug capacity with API production for multiple pipelines.
How large is Lilly's U.S. manufacturing footprint?
In February 2025, Lilly announced an additional $27 billion to build four new U.S. plants; Houston is one of them.
Part of the motivation is building policy goodwill with the Trump administration. Since 2020, Lilly's cumulative commitment to global manufacturing expansion has exceeded $50 billion.
This reflects a broader shift: GLP-1 competition has moved beyond "whose drug is better" to "whose capacity comes online first" — drugmakers are locking in future share with construction speed.
What should investors watch next?
Two key variables: whether capacity build-out keeps pace with demand growth, and the actual prescription conversion rate after Medicare coverage takes hold.
Together, these will determine whether Lilly can close the gap with Novo Nordisk in the oral GLP-1 market.
Put simply = the drug is approved, the factory is underway — but the real race is "can you make enough, fast enough" and "will doctors prescribe it."
市场有风险，内容仅供研究参考，不构成投资建议。